Navigation Links
Suppressing cancer with a master control gene
Date:2/23/2009

Starting with the tiny fruit fly and then moving into mice and humans, researchers at VIB and K. U. Leuven show that expression of the same gene suppresses cancer in all three organisms. Reciprocally, switching off the gene called Ato in flies and ATOH1 in mammals leads to cancer. The authors show there is a good chance that the gene can be switched on again with a drug. They report their findings in two papers in the leading online open access journal PLoS Biology.

All of us begin our lives as a single cell (made when an egg and sperm fuse) which repeatedly divides into the few billion cells that constitute an adult human. During these divisions cells become increasingly differentiated from each other, until in an adult almost all cells are highly specialized to perform a specific function skin cells, liver cells, eye lens cells, nerve cells, etc. Cancer is a collection of cells without a function, which grow when normal genetic controls of cell division are interrupted. Cancer cells are less differentiated than normal cells leading to the hypothesis that the final steps of differentiation prevent cells from becoming cancerous.

New work conducted by Wouter Bossuyt, Bassem Hassan, and colleagues at VIB and K. U. Leuven has tested this theory. They demonstrate that in the fruit fly, master control genes steering the specialization step inhibit tumor formation.

In collaboration with colleagues from the United States, they show that loss of one of those genes, Atonal homolog 1 (ATOH1), causes colon cancer in mice. The gene regulates the last step in the specialization to epithelial cells of the colon. Humans with colon cancer frequently have an inactivated ATOH1 gene, the researchers show.

The researchers could reactivate the gene in human colon cancer cells grown in culture. This caused the tumor cells to stop growing and commit suicide. This exciting, but preliminary, result suggests that it may be possible to switch the gene back on in living patients to target their cancers. Taking this work in the test tube and using it to develop a therapy is an exciting but complicated challenge. Therefore, more work will be required to further understand the role of ATOH1 in suppressing cancer formation.


'/>"/>

Contact: Sally Hubbard
press@plos.org
Public Library of Science
Source:Eurekalert

Related biology news :

1. Link between unexploded munitions in oceans and cancer-causing toxins determined
2. Researchers identify gene linked to aggressive progression of liver cancer
3. New lab evidence suggests preventive effect of herbal supplement in prostate cancer
4. New test for breast cancer will help guide treatment choices
5. Rural areas able to increase screening capacity for colorectal cancer
6. Statin therapy ineffective in breast cancer prevention
7. More than a million cancer survivors declining care due to cost concerns
8. Hispanic women and breast cancer: An understudied group
9. Compounds could be new class of cancer drugs
10. UNC study: Tinkering with the circadian clock can suppress cancer growth
11. Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. (RCA), ... free webinar on Performing Quality Investigations: Getting to Root Cause. ... no charge. , Incomplete investigations are still a major concern to the Regulatory ...
Breaking Biology Technology: